Apellis, Beam to apply base editing for disease discovery

By The Science Advisory Board staff writers

July 2, 2021 -- Apellis Pharmaceuticals and Beam Therapeutics announced an exclusive five-year research collaboration focused on Beam's proprietary base editing technology for the discovery of treatments for disease of the complement system.

The companies will collaborate on six research programs focused on C3 and other complement targets in the eye, liver, and brain, the companies said. The agreement gives Apellis exclusive rights to license each of the six programs and gives the company responsibility for subsequent development.

On its end, Beam will receive $75 million in upfront and near-term milestones from Apellis, $50 million upon signing and an additional $25 million on the one-year anniversary of the contract execution date, the companies said.

The collaboration has an initial term of five years and may be extended up to two years on a per year and program-by-program basis.

Ixaka, SomaLogic partner on aptamer-based, bispecific antibodies
Ixaka and SomaLogic have entered into a research collaboration to support the development of aptamer-based, bispecific therapeutics.
Development 'cookbooks' could speed up gene therapy
Great strides have been made in the development of gene editing tools in the past decade, but translating the technology into real therapies to treat...
Genomic landscape of osteosarcomas reveals why immunotherapy may not be effective
Immune profiling of osteosarcoma has revealed why immune checkpoint inhibitors might not be an effective treatment option for patients with this rare...
Math models improve the effectiveness of immunotherapy
Scientists working at the intersection of math and medicine propose new strategies based on mathematical modeling and known molecular mechanisms to improve...

Copyright © 2021 scienceboard.net

Microscopy and Microanalysis Meeting
July 31 - August 4
Portland, Oregon United States
Glasgow International Health Festival
August 24-27
Glasgow, Glasgow City United Kingdom
Pharma Competitive Intelligence Conference and Exhibition
September 21-22
Newark, New Jersey United States
BioProcess International (BPI) Conference
September 27-30
Boston, Massachusetts United States
Science Advisory Board on LinkedIn
Science Advisory Board on Facebook
Science Advisory Board on Twitter